A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Intra-abdominal Infections
Interventions
DRUG

Metronidazole

Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.

DRUG

Ceftriaxone sodium

Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.

Trial Locations (15)

Unknown

Daiyukai First Hospital, Ichinomiya

Hirosaki National Hospital, Hirosaki

National Hospital Organization Chiba Medical Center, Chiba

National Hospital Organization Kokura Medical Center, Kitakyushu

National Hospital Organization Fukuyama Medical Center, Fukuyama

Hitachi General Hospital, Hitachi

Kawasaki Saiwai Hospital, Kawasaki

Kumamoto Saishunso National Hospital, Koushi

National Hospital Organization Kumamoto Medical Center, Kumamoto

National Hospital Organization Sendai Medical Center, Sendai

Iida Municipal Hospital, Iida

Nagano Prefectural Suzaka Hospital, Suzaka-shi

National Hospital Organization Nagasaki Medical Center, Ohmura

National Hospital Organization Osaka Minami Medical Center, Kawachi-Nagano

Koshigaya Municipal Hospital, Koshigaya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01473836 - A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection | Biotech Hunter | Biotech Hunter